HCPCS Level II code A9598 designates a PET radiopharmaceutical for diagnostic non-tumor identification that is not otherwise classified. This code covers the administered radiotracer product used during PET imaging when the clinical intent is non-oncologic diagnostic evaluation. Nationally, PET radiopharmaceuticals support clinical decision-making across neurology, cardiology, and other non-tumor indications, making clear coding important for billing consistency, coverage determination, and resource allocation.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical scope, typical sites of service, and the role of A9598 in non-tumor PET imaging workflows. The publication summarizes common billing modifiers and payer coverage context, outlines typical service settings, and highlights where policy updates or coding clarification may affect claim processing. The content is intended to inform coding staff, revenue cycle professionals, and policy analysts about the code’s purpose, expected clinical uses, and considerations for national billing practices.